CTOs on the Move

Corktown Health

www.corktownhealth.org

 
Moderna COVID-19 Vaccine Clinic and Health Fair Let’s do our part! Corktown Health is offering the Moderna COVID-19 vaccine on 5/21, 5/28, 6/1, 6/4, and 6/5 from 8:30am to 1pm. We will also be offering vaccines at the Hazel Park Recreation Center on 6/...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Asymchem Laboratories

Asymchem Laboratories is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Odyssey Behavioral Healthcare

Odyssey Behavioral Health consists of a growing portfolio of quality behavioral health facilities with evidence-based clinical care.

Veristat

Veristat, a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.

MicroPort

(877) 663-7674

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.